[123I]Iodometomidate imaging in adrenocortical carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 7, 2013, Pages 2755-2764

  Kreissl, Michael C ^a   Schirbel, Andreas ^a   Fassnacht, Martin ^a   Haenscheid, Heribert ^a   Verburg, Frederik A ^a,b   Bock, Stefanie ^a   Saeger, Wolfgang ^c   Knoedler, Pascal ^a   Reiners, Christoph ^a   Buck, Andreas K ^a   Allolio, Bruno ^a   Hahner, Stefanie ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c Marienkrankenhaus ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CYTOTOXIC AGENT; HYDROCORTISONE; IODOMETOMIDATE I 123; IODOMETOMIDATE I 131; KI 67 ANTIGEN; MITOTANE; RADIOPHARMACEUTICAL AGENT; STEROID 11BETA MONOOXYGENASE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ETOMIDATE; IODOPHENYL METOMIDATE; RADIOACTIVE IODINE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ALDOSTERONE RELEASE; ARTICLE; BONE METASTASIS; CASE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; DRUG RETENTION; DYSPNEA; FEMALE; FLUSHING; GAMMA CAMERA; HUMAN; HUMAN TISSUE; HYDROCORTISONE RELEASE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; PLEURA METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOISOTOPE THERAPY; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT TISSUE METASTASIS; SPECT CT CAMERA SYSTEM; SPECT CT HYBRID IMAGING; TACHYCARDIA; WHOLE BODY SCINTISCANNING; ADRENAL CORTEX; ADRENAL CORTEX TUMOR; BLOOD; CANCER STAGING; COHORT ANALYSIS; METASTASIS; MIDDLE AGED; PATHOLOGY; PILOT STUDY; SCINTISCANNING; SECRETION (PROCESS); TUMOR RECURRENCE; WHOLE BODY IMAGING;

ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ALDOSTERONE; COHORT STUDIES; ETOMIDATE; FEMALE; HUMANS; HYDROCORTISONE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84879958677     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3261     Document Type: Article

References (30)

1. 123I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab. 2008;93:2358-2365.
2. Mitterhauser M, Wadsak W, Wabnegger L, et al. In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats. Eur J Nucl Med Mol Imaging. 2003;30:1398-1401. (Pubitemid 37247958)
3. Zolle IM, Berger ML, Hammerschmidt F, Hahner S, Schirbel A, Peric-Simov B. New selective inhibitors of steroid 11β-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues. J Med Chem. 2008;51:2244-2253. (Pubitemid 351503279)
4. Hennings J, Hellman P, Ahlström H, Sundin A. Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol. 2009;69:314-323.
5. 11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab. 2006;91:1410-1414.
6. 18F-FDG. J Nucl Med. 2004;45:972-979.
7. 11C-metomidate. Eur J Nucl Med Mol Imaging. 2004;31:1224-1230.
8. Freitas JE, Grekin RJ, Thrall JH, Gross MD, Swanson DP, Beierwaltes WH. Adrenal imaging with iodomethyl-norcholesterol (I-131) in primary aldosteronism. J Nucl Med. 1979;20:7-10. (Pubitemid 9100353)
9. Gordon L, Levine JH, Mayfield RK, Buse MG. Adrenal imaging with iodomethyl-norcholesterol (I-131) in primary aldosteronism. J Nucl Med. 1979;20:897-898.
10. Hwang I, Balingit AG, Georgitis WJ, Sisson JC, Shapiro B. Adrenocortical SPECT using iodine-131 NP-59. J Nucl Med. 1998;39:1460-1463. (Pubitemid 28373579)
11. 131I-6 β iodomethyl-norcholesterol uptake to discriminate subclinical and preclinical functioning adrenal incidentaloma. J Nucl Med. 2003;44:1057-1064.
12. Maurea S, Imbriaco M, Mollica C, Pace L, Salvatore M. Quantitative imaging characterization of hypersecreting or nonhypersecreting adrenal adenomas: comparison between iodine-131 norcholesterol uptake and magnetic resonance signal intensity ratios. Nucl Med Commun. 2011;32:535-541.
13. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med. 2001;42:884-892. (Pubitemid 32537435)
14. Nocaudie-Calzada M, Huglo D, Lambert M, et al. Efficacy of iodine-131 6β-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism. Eur J Nucl Med. 1999;26:1326-1332. (Pubitemid 29467028)
15. Wong KK, Komissarova M, Avram AM, Fig LM, Gross MD. Adrenal cortical imaging with I-131 NP-59 SPECT-CT. Clin Nucl Med. 2010;35:865-869.
16. Khan TS, Sundin A, Juhlin C, Långström B, Bergström M, Eriksson B. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 2003;30:403-410. (Pubitemid 36692866)
17. Hahner S, Kreissl MC, Fassnacht M, et al. [131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97:914-922.
18. 123I]IMTO-SPECT/CT. J Clin Endocrinol Metab. 2013;98(4):1508-1518.
19. 123/131I] Iodometomidate as a radioligand for functional diagnosis of adrenal disease: synthesis, structural requirements and biodistribution. Radiochim Acta. 2004;92:297-303.
20. Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95:4925-4932.
21. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging. 2010;37:1669-1678.
22. Caoili EM, Korobkin M, Brown RK, Mackie G, Shulkin BL. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol. 2007;14:468-475. (Pubitemid 46420545)
23. 18F- Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab. 2009;94:1713-1722.
24. Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006;91:920-925. (Pubitemid 43357759)
25. 18F] fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:2665-2671.
26. Rao SK, Caride VJ, Ponn R, Giakovis E, Lee SH. F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med. 2004;29:300-302. (Pubitemid 38506996)
27. 18F- fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol. 2004;150:789-792.
28. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
29. Touitou Y, Moolenaar AJ, Bogdan A, Auzéby A, Luton JP. o,p′-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis. Eur J Clin Pharmacol. 1985;29:483-487. (Pubitemid 16192608)
30. Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5a-reductase explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013;98(1):161-171.